CWM
ABBV icon

Calamos Wealth Management’s AbbVie ABBV Stock Holding History

Calamos Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.01M Sell
15,919
-357
-2% -$76.8K 0.12% 115
2026
Q1 		$3.54M Buy
16,276
+1,401
+9% +$311K 0.12% 107
2025
Q4 		$3.4M Buy
14,875
+146
+1% +$33.3K 0.12% 102
2025
Q3 		$3.41M Buy
14,729
+6,298
+75% +$1.28M 0.12% 101
2025
Q2 		$1.56M Buy
8,431
+327
+4% +$60.8K 0.07% 132
2025
Q1 		$1.7M Sell
8,104
-956
-11% -$186K 0.08% 110
2024
Q4 		$1.61M Buy
9,060
+208
+2% +$38.2K 0.08% 113
2024
Q3 		$1.75M Buy
8,852
+693
+8% +$129K 0.09% 110
2024
Q2 		$1.4M Sell
8,159
-565
-6% -$93.6K 0.07% 122
2024
Q1 		$1.59M Sell
8,724
-1,942
-18% -$335K 0.09% 115
2023
Q4 		$1.65M Sell
10,666
-1,328
-11% -$194K 0.1% 103
2023
Q3 		$1.79M Buy
11,994
+379
+3% +$55.6K 0.14% 100
2023
Q2 		$1.56M Buy
11,615
+375
+3% +$55K 0.11% 111
2023
Q1 		$1.79M Buy
11,240
+959
+9% +$147K 0.14% 103
2022
Q4 		$1.66M Sell
10,281
-17
-0.2% -$2.61K 0.13% 112
2022
Q3 		$1.38M Sell
10,298
-1,975
-16% -$283K 0.12% 113
2022
Q2 		$1.88M Buy
12,273
+71
+0.6% +$10.8K 0.17% 100
2022
Q1 		$1.98M Buy
12,202
+3,038
+33% +$441K 0.15% 107
2021
Q4 		$1.24M Sell
9,164
-87
-0.9% -$10.3K 0.09% 144
2021
Q3 		$998K Sell
9,251
-23
-0.2% -$2.63K 0.08% 160
2021
Q2 		$1.04M Buy
9,274
+4,743
+105% +$534K 0.08% 159
2021
Q1 		$490K Buy
4,531
+1,130
+33% +$121K 0.04% 226
2020
Q4 		$364K Buy
3,401
+1,071
+46% +$103K 0.03% 232
2020
Q3 		$204K Buy
+2,330
New +$219K 0.02% 250
2020
Q1 		– Sell
-2,303
Closed -$204K – 238
2019
Q4 		$204K Sell
2,303
-625
-21% -$51.9K 0.02% 227
2019
Q3 		$222K Buy
+2,928
New +$201K 0.03% 216
2019
Q2 		– Sell
-3,350
Closed -$270K – 238
2019
Q1 		$270K Sell
3,350
-11,369
-77% -$930K 0.04% 193
2018
Q4 		$1.36M Sell
14,719
-39,700
-73% -$3.49M 0.2% 89
2018
Q3 		$5.15M Sell
54,419
-3,935
-7% -$373K 0.64% 48
2018
Q2 		$5.41M Sell
58,354
-6,893
-11% -$673K 0.67% 49
2018
Q1 		$6.18M Buy
65,247
+51,001
+358% +$5.6M 0.77% 47
2017
Q4 		$1.38M Buy
+14,246
New +$1.34M 0.18% 98
2016
Q2 		– Sell
-31,041
Closed -$1.77M – 240
2016
Q1 		$1.77M Buy
31,041
+13,887
+81% +$774K 0.34% 98
2015
Q4 		$1.02M Sell
17,154
-2,354
-12% -$136K 0.2% 146
2015
Q3 		$1.06M Buy
+19,508
New +$1.27M 0.25% 132
2015
Q2 		– Sell
-5,605
Closed -$328K – 223
2015
Q1 		$328K Sell
5,605
-695
-11% -$42K 0.08% 185
2014
Q4 		$412K Buy
+6,300
New +$397K 0.12% 175

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Calamos Wealth Management's ABBV Position: Q2 2026 in Review

Calamos Wealth Management reduced its AbbVie (ABBV) stake by 2.2% in Q2 2026, selling an estimated $76.8K and leaving 15,919 shares worth $4.01M. The position accounts for 0.12% of the portfolio, ranked #115.

Calamos Wealth Management first reported a position in ABBV in Q4 2014 and has held it in 37 quarters since. The position peaked at $6.18M in Q1 2018. 2,841 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Calamos Wealth Management held 15,919 shares of AbbVie worth $4.01M as of Q2 2026.
  • Calamos Wealth Management sold 357 AbbVie shares in Q2 2026, an estimated $76.8K.
  • AbbVie made up 0.12% of Calamos Wealth Management's portfolio in Q2 2026, its #115 holding.
  • Calamos Wealth Management first reported a position in AbbVie in Q4 2014 and has held it in 37 quarters since.
  • Calamos Wealth Management's AbbVie position peaked at $6.18M in Q1 2018.
  • 2,841 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Calamos Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.